1 / 44

Terapia dell’ ipertensione arteriosa nel paziente diabetico

Terapia dell’ ipertensione arteriosa nel paziente diabetico. Prof. P. Pauletto Dipartimento di Medicina - DIMED Università degli Studi di Padova Dipartimento di Medicina Interna U.L.S.S. n° 9, Ospedale di Treviso. SUMMARY. Epidemiology BP target: old vs. new guidelines

wstacy
Download Presentation

Terapia dell’ ipertensione arteriosa nel paziente diabetico

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Terapia dell’ ipertensione arteriosa nel paziente diabetico Prof. P. Pauletto Dipartimento di Medicina - DIMED Università degli Studi di Padova Dipartimento di Medicina Interna U.L.S.S. n° 9, Ospedale di Treviso

  2. SUMMARY • Epidemiology • BP target: old vs. new guidelines • Choice of medication • - efficacy • - BP variability • - tolerability • Conclusion

  3. Hypertension prevalence among DM2 patients Colosia, Diabetes, Metabolic Syndrome and Obesity:Targets and Therapy, 2013

  4. The impact of hypertension on CV outcomesin patients with incident DM in the Framingham cohort Shemesh, Am J Cardiol, 2012

  5. SUMMARY • Epidemiology • BP target: old vs. new guidelines • Choice of medication • - efficacy • - BP variability • - tolerability • Conclusion

  6. Target pressorio e strategia iniziale di trattamento negli ipertesi e nei diabetici ipertesi PAS (mmHg) PAD <140 Ipertesi non Diabetici <90 <80 (75)* <130 (125)* Ipertesi Diabetici Norme igienico-dietetiche (max 3 mesi) seguite da trattamento farmacologico (Ace-inibitori, ARBs, ß-bloccanti, diuretici) 80-89 130-139 se Norme igienico-dietetiche e trattamento farmacologico (Ace-inibitori, ARBs, ß-bloccanti, diuretici) 90 140 se American Diabetes Association. Diabetes Care 2002;25:S71-S73 * Se proteinuria >1g/die

  7. Mean systolic and diastolic blood pressures over nine years in 297 patients in group assigned to tight control of blood pressure and 156 in group assigned to less tight control 15416 14414 Tight <150/85 mmHg Less tight <180/105 mmHg 877 82 7

  8. Proportions of patients who die of disease related to diabetes (myocardial infarction, sudden death, stroke, peripheral vascular disease, and renal failure)

  9. HOT STUDY Events in patients with diabetes in relation to target blood pressure groups (n=501, 501, and 499 in the target groups 90 mm Hg, 85 mm Hg, and 80 mm Hg, respectively)

  10. ESC Hypertension Guidelines 2007

  11. Achieved systolic blood pressure (SBP) in patients randomized to more active (filled rectangles) or less active (open rectangles) treatment in trials on (a) patients with diabetes mellitus Zanchetti et al. J hypertension 2009

  12. Mean Systolic Blood-Pressure Levels at Each Study Visit - ACCORD study - <140 mmHg <120 mmHg

  13. Primary composite outcome - ACCORD -

  14. All Causes MortalityIntensive (≤ 130mmHg SBP) vs. Standard (≤ 135 mmHg SBP)blood pressure control Bangalore S, Circulation,2011

  15. Cardiovascular MortalityIntensive (≤ 130mmHg SBP) vs. Standard (≤ 135 mmHg SBP)blood pressure control Bangalore S, Circulation,2011

  16. A SBP goal <140 mmHg in hypertensive patients ESC-ESH 2013 Guidelines

  17. American Diabetes Association 2014

  18. JNC 8, 2014

  19. SUMMARY • Epidemiology • BP target: old vs. new guidelines • Choice of medication • - efficacy • - BP variability • - tolerability • Conclusion

  20. NEFROPATIA CONCLAMATA Aumento creatininemia, Riduzione GFR Evoluzione naturale della nefropatia diabetica e trials clinici A B D C Tempo Inizio della proteinuria Nefropatia terminale NEFROPATIA INCIPIENTE Iperfiltrazione, microalbuminuria, aumento pressione arteriosa NEFROPATIA PRECLINICA RENAAL IDNT IRMA 2

  21. Progression to Diabetic Nephropathy in Hypertensive Patients with Type 2 Diabetes and Persistent Microalbuminuria. Parving HH, 2001

  22. Conclusions Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.

  23. Occurrence of new-onset microalbuminuria during the 48-month follow-up period in the ROADMAP Study H.Haller, NEJM, 2011

  24. Hazard ratios for risk of stroke and acute coronary events in ASCOT-BPLA patients with mean SBP during follow-up less than the median value for the trial population (<142.8 mmHg) by decile of SD Rothwell at al. Lancet 2010

  25. Circulation, 2013; 128: 1325-1334

  26. The ADVANCE trialBP variability as a predictor of CV disease in DM2 Jun Hata; Circulation, 2013; 128: 1325-1334

  27. A comparison of the 24-h systolic and diastolic ambulatory blood pressure smoothness indices for five antihypertensive combination therapies and placebo; data are based on three trials involving 1420 combination therapy-treated patients. Parati G et al. 2010

  28. Hypertension 2012; 59:1132-1138

  29. Effect of 24 weeks of treatment on BP variability: Olmesartan + HCTZ vs. Olmesartan + Azelnidipine Matsui Y, Hypertension 2012

  30. Christine Grimm; Juliane Köberlein; Waldemar Wiosna; Jutta Kresimon; Peter Kiencke; Reinhard Rychlik Christos V Rizos, Moses S Elisaf

  31. Odd ratios for incident diabetes in a meta-analysis of 22 randomized clinical trials (143153 patients) using diuretic as reference William J Elliott, Peter M Meyer. Lancet 2007; 369: 201-07

  32. Incidence of new-onset diabetes mellitus (DM) in controlled trials of antihypertensive drug therapies *p < 0.05 for all results except NORDIL and SCOPE (n.s.) **Diuretic used by > 80% patients Current Medical Research and Opinion 2004;20:359-367

  33. Persistence to antihypertensive treatment with different drug therapies % persistent PR Conlin et al, Clin Ther,2001

  34. NICE 2013 - Choice of drugs (1) • Most patients with diabetes will require combination therapy with multiple antihypertensive drugs to achieve good control. • First-line BP-lowering therapy should be a once-daily, generic ACE inhibitor. Exceptions to this are: • First-line BP-lowering therapy for a person of African-Caribbean descent should be an ACE inhibitor plus either a diuretic or a generic calcium-channel antagonist (calcium-channel blocker). • A calcium-channel blocker should be the first-line BP-lowering therapy for a woman for whom there is a possibility of her becoming pregnant.

  35. NICE 2013 - Choice of drugs (3) • An AIIRA should be substituted for the ACE inhibitor if there are persistent side-effects (eg, chronic cough) but not if there is deteriorating renal function or hyperkalaemia. • Patients with diabetic nephropathy (including microalbuminuria) should be prescribed the full (or maximum-tolerated) dose of ACE inhibitor or AIIRA to achieve maximum renal benefit. • Monitor renal function and electrolytes regularly for all patients on ACE inhibitors or AIIRAs, particularly after any change of dose. • If control is still inadequate on third-line therapy, referral to a specialist should be considered.

  36. JNC 8, 2014

  37. SUMMARY • Epidemiology • BP target: old vs. new guidelines • Choice of medication • - efficacy • - BP variability • - tolerability • Conclusion

  38. Recommended BP targets in DM2 D. Lorber; Diabetes, Metabolic Syndrome and Obesity: Agents and Therapy; 2014

  39. Treatment of the diabetic hypertensive Chokshi NP, et al. Heart 2013;

  40. Controllo del rischio CV nel paziente obeso/diabetico/iperteso • Ridurre il peso • Prevenire / controllare il DM • Iniziare la terapia antiipertensiva precocemente • Privilegiare ARBs e ACEI

More Related